Role of Shirishadi kwath in management of Asthma
Not Applicable
- Conditions
- Health Condition 1: null- patient diagnosed with Asthma
- Registration Number
- CTRI/2018/04/013336
- Lead Sponsor
- Campus Director
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients having the classical symtoms of tamaka shwasa will be included
Exclusion Criteria
1.Patients of cardiac asthma, COPD, emphysema, post tubercular lung fibrosis.
2.Patients having any other systemic disorder like diabetes, HTN, tuberculosis etc
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The Trail Yet to be StartedTimepoint: June 2019
- Secondary Outcome Measures
Name Time Method the trial have not started yetTimepoint: the trial have not started yet
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Shirishadi kwath's anti-inflammatory effects in tamak shwas (asthma) pathogenesis?
How does CTRI/2018/04/013336 compare Shirishadi kwath to standard bronchodilator therapies in asthma exacerbation frequency?
Which biomarkers (e.g., IgE, eosinophil counts) correlate with Shirishadi kwath response in clinicopathological asthma subtypes?
What adverse events are reported in Ayurvedic asthma trials using Shirishadi kwath formulations and their mitigation strategies?
Are there synergistic effects when combining Shirishadi kwath with leukotriene receptor antagonists in asthma management?